Recently, "Forbes China Go-International Series 30&30" award ceremony was held in Xiamen, China. Among the distinguished companies honored, Henlius (2696.HK) stood out alongside Aliyun, Lenovo, Iflytek, and SHEIN, being selected as one of the "Forbes China Go-International Series Top 30". Remarkably, Henlius was the sole biopharma company on the list. This accolade not only acknowledges Henlius' relentless pursuit of globalization but also underscores the company’s exceptional accomplishments in the international biopharmaceutical arena.
This year, Forbes China has launched the second installment of its Forbes China-International Global series, celebrating Chinese companies that have made a remarkable impact on their industries through innovative global branding efforts. By holistically assessing their globalization development, brand influence, innovation prowess, and financial health, the series identifies the leaders excelling in the "Going Out - Bringing In" initiative. Forbes China highlights that the synergy between "innovation driving international expansion" and "international expansion fostering innovation" has created a virtuous cycle propelling technological, biomedical, and other enterprises to new heights. Among these, Henlius exemplifies the transition from participant to leader on the global stage, symbolizing the rising prominence of Chinese firms in the international arena.
As a pioneer and leader of among Chinese biopharma companies venturing overseas, Henlius has demonstrated remarkable performance on the international stage. To date, six products have been launched in China, three have been approved for marketingin overseas markets, reaching over 50 countries and regions across Asia, Europe, Latin America, North America, and Oceania, benefiting more than 690,000 patients worldwide. By adhering to a strategy of differentiated innovation, Henlius continues to enrich and optimize its product pipeline, encompassing over 50 molecules and R&D platforms. These include monoclonal antibodies (mAb), antibody-drug conjugates (ADC), fusion proteins, small molecule drugs, and other drug forms. Over the qualifying period, the company successfully managed a total of 600 submissions,which 500 were approved in China, the United States, the European Union, Canada, Indonesia, Japan, and other regions. It has also conducted international multi-center clinical trials, accelerating its product globalization efforts. In its pursuit of innovation and global technological advancement, Henlius has established world-class high-quality production capacity and quality systems, ensuring stable commercial supply to markets in China, Europe, Southeast Asia, Latin America, and the Middle East. The facilities and quality systems have gained certifications from GMP authorities in China, the United States, Europe, PIC/S member countries, Brazil, and Indonesia, ensuring the global consistency of product quality. Henlius collaborates with over 20 international business partners to expand its global commercial footprint, gaining access to and selling licenses in numerous new markets, thereby injecting fresh vitality into its overseas growth. The company is also actively promoting the internationalization of its talent pool, having established subsidiaries in various overseas locations and employing local staff in the United States, Australia, Singapore, Japan, and other countries, underscoring its commitment to a global strategic vision.
Looking ahead, Henlius will remain rooted in China while expanding its global presence, steadfastly committed to its mission of “benefiting patients worldwide with high-quality biopharmaceuticals.” The company will persist in advancing technological innovation and expanding its reach in international markets, striving to secure a leading position in the global biopharma industry. Through these efforts, Henlius aims to bring enhanced health benefits to patients across the globe.